Discover March 2025’s top biotech deals, featuring major collaborations in small molecules, bispecific antibodies and protein ...

FDA approves Sanofi's Qfitlia, the first antithrombin-lowering therapy for hemophilia A or B, reducing bleeding episodes with ...

HBM Healthcare Investments AG / Key word (s): Annual Results HBM Healthcare Investments expects to report a net profit of CHF 19 million for the 2024/2025 financial year 01-Apr-2025 / 17:49 CET/CEST ...

In a bid to pursue growing sales, Sanofi doubled down on investing in immunology with the $600 million upfront buyout of Dren Bio’s clinical stage bispecific antibody. The antibody has been evaluated ...

Sanofi hires former GSK development head Chris Corsico as global R&D head, replacing Dietmar Berger who left for Gilead. Move aligns with €2B R&D investment strategy.

The Sanofi drug, known as fitusiran and now Qfitlia, was approved on Friday for a broad group of people with the rare ...

In connection with the start of the phase 3 trials of PCV21, Sanofi has expanded its alliance with South Korea-based SK Bio, first signed more than a decade ago, paying an upfront fee of €50 ...

Sanofi said it would also apply its mRNA vaccine platform – acquired along with Translate Bio earlier this year – to find other acne vaccine candidates that could start clinical trials in 2023.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...